Brands & Strategies: Rheumatoid Arthritis

Table of Contents

Table of Contents

Table of Exhibits

Executive Summary

Section 1: Rheumatoid Arthritis Patient Populations

• Background
• Rheumatoid Arthritis Prevalence and Diagnosis
• US
• Europe
• Japan

Section 2: Rheumatoid Arthritis Treatment Overview

• Rheumatoid Arthritis Treatment
  • Disease-Modifying Therapies
  • Palliative Agents

Section 3: Major Markets for Rheumatoid Arthritis Treatment

• Market Overview
  • Rheumatoid Arthritis Drug Sales by Region
  • Rheumatoid Arthritis Drug Sales by Class
• Market Forecast
  • Key Events
  • Drug Pricing
  • Formulary Placement
  • TNF-α Inhibitor Market
  • Selective Costimulation Modulator Market
  • B-Cell-Targeted Therapy Market
  • Interleukin-Based Therapy Market
  • Conventional DMARD Market

Section 4: Competitive Analysis

• Overview
• Competitive Landscape, 2005-2010
  • Rheumatoid Arthritis Market by Competitor
  • Promotional Spending

Enbrel

• Approval History
• Sales and Market Position
• Enbrel Competitive Analysis
• Promotional Spending
• Life Cycle Management
• Strategic Positioning
• Wyeth
  • Product Portfolio
  • Rheumatoid Arthritis Pipeline
  • Strategic Positioning
• Amgen
  • Product Portfolio
  • Rheumatoid Arthritis Pipeline
  • Strategic Positioning

Remicade

• Approval History
• Sales and Market Position
• Remicade Competitive Analysis
• Promotional Spending
• Life Cycle Management
• Strategic Positioning
• Centocor
  • Product Portfolio
  • Rheumatoid Arthritis Pipeline
  • Strategic Positioning
• Schering-Plough
  • Product Portfolio
  • Rheumatoid Arthritis Pipeline
  • Strategic Positioning

Humira

• Approval History
• Sales and Market Position
• Humira Competitive Analysis
• Promotional Spending
• Life Cycle Management
• Strategic Positioning
• Abbott
  • Product Portfolio
  • Rheumatoid Arthritis Pipeline
  • Strategic Positioning

Orencia

• Approval History
• Sales and Market Position
• Orencia Competitive Analysis
• Promotional Spending
• Life Cycle Management
• Strategic Positioning
• Bristol-Myers Squibb
  • Product Portfolio
  • Rheumatoid Arthritis Pipeline
  • Strategic Positioning

Rituxan/MabThera

• Approval History
• Sales and Market Position
• Rituxan/MabThera Competitive Analysis
• Promotional Spending
• Life Cycle Management
• Strategic Positioning
• Roche
  • Product Portfolio
  • Rheumatoid Arthritis Pipeline
  • Strategic Positioning

Key Drugs To Launch

• UCB' s Cimzia
• Centocor/Schering-Plough/Tanabe/Janssen Pharmaceutical KK' s Golimumab
• Roche/Chugai' s Actemra

Section 5: Supplementary Market Analysis and Methodology

Acronyms and Abbreviations

Methodology

• Epidemiological Forecast Methodology
• Market Forecast Methodology
• Competitive Analysis Methodology

Bibliography

Table of Exhibits

Executive Summary

• Exhibit ES-1: Disease-Modifying RA Market ($US), Major Markets, 2005-2010
• Exhibit ES-2: Disease-Modifying RA Market by Competitor, 2005 and 2010

Section 1: Rheumatoid Arthritis Patient Populations

• Exhibit 1-1: Rheumatoid Arthritis Prevalence and Diagnosis, Major Markets
• Exhibit 1-2: Rheumatoid Arthritis Prevalence and Diagnosis, US
• Exhibit 1-3: Rheumatoid Arthritis Prevalence and Diagnosis, Europe
• Exhibit 1-4: Rheumatoid Arthritis Prevalence and Diagnosis, Europe, Continued
• Exhibit 1-5: Rheumatoid Arthritis Prevalence and Diagnosis, Japan

Section 2: Rheumatoid Arthritis Treatment Overview

• Exhibit 2-1: Drug Classes Used for the Treatment of RA

Section 3: Major Markets for Rheumatoid Arthritis Treatment

• Exhibit 3-1: Disease-Modifying RA Market ($US), Major Markets, 2005-2010 (Graphical Format)
• Exhibit 3-2: Disease-Modifying RA Market ($US), Major Markets, 2005-2010 (Tabular Format)
• Exhibit 3-3: Market for Disease-Modifying RA Therapies ($US), by Country, Major Markets, 2005-2010
• Exhibit 3-4: Market for Disease-Modifying RA Therapies, by Country, as a % of Total, Major Markets, 2005 and 2010
• Exhibit 3-5: Market for Disease-Modifying RA Therapies ($US), by Drug Class, Major Markets, 2005-2010
• Exhibit 3-6: Key Events , RA, 2005-2010
• Exhibit 3-7: Price to Treat per Day ($US), TNF-α Inhibitors, 2005
• Exhibit 3-8: Price to Treat per Day ($US), Selective Costimulation Modulators, 2005
• Exhibit 3-9: Price to Treat per Day ($US), B-Cell-Targeted Therapies, 2005
• Exhibit 3-10: Price to Treat per Day ($US), Interleukin-Based Therapies, 2005
• Exhibit 3-11: Price to Treat per Day ($US), Conventional DMARDs, 2005-2010
• Exhibit 3-12: Price to Treat per Day ($US), Conventional DMARDs, 2005-2010, Continued
• Exhibit 3-13: Conventional DMARD Pricing, Brand vs. Generic Price, 2005
• Exhibit 3-14: Conventional DMARD Pricing, Brand vs. Generic Price, 2005, Continued
• Exhibit 3-15: US Formulary Placement of RA Conventional DMARDs
• Exhibit 3-16: US Formulary Placement of RA Biologics
• Exhibit 3-17: TNF-α Inhibitor Market ($US), by Drug, Major Markets, 2005-2010 (Graphical Format)
• Exhibit 3-18: TNF-α Inhibitor Market ($US), by Country, Major Markets, 2005-2010 (Tabular Format)
• Exhibit 3-19: TNF-α Inhibitor Market ($US), by Drug, Major Markets, 2005-2010 (Tabular Format)
• Exhibit 3-20: TNF-α Inhibitor Market Share, by Brand and Region, 2005 and 2010
• Exhibit 3-21: Selective Costimulation Modulators Market ($US), by Drug, Major Markets, 2005-2010
• Exhibit 3-22: Selective Costimulation Modulator Market ($US), by Country, 2005-2010
• Exhibit 3-23: B-Cell-Targeted Therapy Market ($US), by Drug, Major Markets, 2005-2010
• Exhibit 3-24: B-Cell-Targeted Therapy Market ($US), by Country, 2005-2010
• Exhibit 3-25: Interleukin-Based Therapy Market ($US), by Drug, Major Markets, 2005-2010 (Graphical Format)
• Exhibit 3-26: Interleukin-Based Therapies Market ($US), by Country, 2005-2010
• Exhibit 3-27: Interleukin-Based Therapies Market ($US), by Drug, Major Markets, 2005-2010 (Tabular Format)
• Exhibit 3-28: Interleukin-Based Therapy Market Share, by Brand and Region, 2005 and 2010
• Exhibit 3-29: Conventional DMARDs Market ($US), by Drug, Major Markets, 2005-2010 (Graphical Format)
• Exhibit 3-30: Conventional DMARDs Market ($US), by Country, 2005-2010
• Exhibit 3-31: Conventional DMARDs Market ($US), by Drug, Major Markets, 2005-2010 (Tabular Format)
• Exhibit 3-32: Conventional DMARD Market Share, by Drug and Region, 2005 and 2010

Section 4: Competitive Analysis

• Exhibit 4-1: RA Market Competitive Position, 2005-2010
• Exhibit 4-2: Disease-Modifying RA Market ($US), by Company, 2005-2010
• Exhibit 4-3: Promotional Spending for RA Biologics, by Company, 2005
• Exhibit 4-4: Promotional Spending Among RA Biologics, 2005
• Exhibit 4-5: Timeline of Enbrel' s RA Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-6: Summary of Key Clinical Trials Supporting Enbrel' s RA Approvals
• Exhibit 4-7: Summary of Key Clinical Trials Supporting Enbrel' s RA Approvals, Continued
• Exhibit 4-8: Summary of Wyeth' s RA Product Portfolio, 2006
• Exhibit 4-9: Summary of Amgen' s RA Product Portfolio, 2006
• Exhibit 4-10: Amgen' s Major-Market RA Revenues by Drug, 2005-2010
• Exhibit 4-11: Timeline of Remicade' s RA Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-12: Summary of Key Clinical Trials Supporting Remicade' s RA Approvals
• Exhibit 4-13: Summary of Centocor' s RA Product Portfolio, 2006
• Exhibit 4-14: Centocor' s Major-Market RA Revenues by Drug, 2005-2010
• Exhibit 4-15: Summary of Schering-Plough' s RA Product Portfolio, 2006
• Exhibit 4-16: Schering-Plough' s Major-Market RA Revenues by Drug, 2005-2010
• Exhibit 4-17: Timeline of Humira' s RA Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-18: Summary of Key Clinical Trials Supporting Humira' s RA Approvals
• Exhibit 4-19: Summary of Key Clinical Trials Supporting Humira' s RA Approvals, Continued
• Exhibit 4-20: Summary of Abbott' s RA Product Portfolio, 2006
• Exhibit 4-21: Timeline of Orencia' s RA Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-22: Summary of Key Clinical Trials Supporting Orencia' s RA Approvals
• Exhibit 4-23: Summary of BMS' RA Product Portfolio, 2006
• Exhibit 4-24: Timeline of Rituxan/MabThera' s RA Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-25: Summary of Key Clinical Trials Supporting Rituxan/MabThera' s RA Approvals
• Exhibit 4-26: Summary of Key Clinical Trials Supporting Rituxan/MabThera' s RA Approvals, Continued
• Exhibit 4-27: Summary of Roche' s RA Product Portfolio, 2006
• Exhibit 4-28: Roche' s Major-Market RA Revenues by Drug, 2005-2010
• Exhibit 4-29: Anticipated RA Launch Dates for Emerging RA Biologics, 2007-2010

Section 5: Supplementary Market Analysis and Methodology

• Exhibit 5-1: Total Enbrel Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-2: Total Remicade Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-3: Total Humira Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-4: Total Cimzia Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-5: Total Golimumab Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-6: Total Kineret Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-7: Total Actemra Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-8: Total Methotrexate Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-9: Total Leflunomide Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-10: Total Sulfasalazine Market ($US), by Country, Major Markets, 2005-2010
• Exhibit 5-11: Total Hydroxychloroquine Market ($US), by Country, Major Markets, 2005-2010